Voriconazole For Chronic Bronchopulmonary Aspergillosis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Aspergillosis
Interventions
DRUG

Voriconazole

"Voriconazole oral : loading dose on day 1 : 400mg/12 hours; maintenance dose 200 mg /12 hours for 6 to 12 months depending on clinical response.~Alternatively, patients may start on Voriconazole, IV, for 7 days loading dose, 6mg/Kg/12 hours on day one and maintenance dose 4 mg/Kg/12 hours"

Trial Locations (18)

14033

Pfizer Investigational Site, Caen

22101

Pfizer Investigational Site, Dinan

29609

Pfizer Investigational Site, Brest

34295

Pfizer Investigational Site, Montpellier

38043

Pfizer Investigational Site, Grenoble

44093

Pfizer Investigational Site, Nantes

49033

Pfizer Investigational Site, Angers

51092

Pfizer Investigational Site, Reims

59037

Pfizer Investigational Site, Lille

69394

Pfizer Investigational Site, Lyon

75010

Pfizer Investigational Site, Paris

75877

Pfizer Investigational Site, Paris

75970

Pfizer Investigational Site, Paris

76031

Pfizer Investigational Site, Rouen

86021

Pfizer Investigational Site, Poitiers

92150

Pfizer Investigational Site, Suresnes

93000

Pfizer Investigational Site, Bobigny

94640

Pfizer Investigational Site, Bris Sous Forges

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00159822 - Voriconazole For Chronic Bronchopulmonary Aspergillosis | Biotech Hunter | Biotech Hunter